China’s CDE clarifies implementation of legislative reforms speeding drug approval

China’s Center for Drug Evaluation (CDE) has released draft regulations implementing recent legal reforms including guidelines for conditional approval and working procedures for breakthrough designation and priority review that could speed approval of new therapies.

The center, which released the regulations Nov. 8, has extended its initial Nov. 13 deadline for public comments on the regulations to Nov. 22.

China’s FDA

Read the full 600 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE